| Title |
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
|
|---|---|
| Published in |
Applied Health Economics and Health Policy, June 2019
|
| DOI | 10.1007/s40258-019-00489-0 |
| Pubmed ID | |
| Authors |
Carsten Hirt, Sergio Iannazzo, Silvia Chiroli, Lisa J. McGarry, Philipp le Coutre, Leif Stenke, Torsten Dahlén, Jeffrey H. Lipton |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 18% |
| Student > Ph. D. Student | 4 | 14% |
| Student > Master | 2 | 7% |
| Lecturer | 1 | 4% |
| Other | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 13 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Nursing and Health Professions | 2 | 7% |
| Economics, Econometrics and Finance | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 13 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2021.
All research outputs
#6,989,215
of 22,919,505 outputs
Outputs from Applied Health Economics and Health Policy
#302
of 778 outputs
Outputs of similar age
#127,757
of 351,889 outputs
Outputs of similar age from Applied Health Economics and Health Policy
#10
of 23 outputs
Altmetric has tracked 22,919,505 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 778 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,889 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.